A healthcare-focused Growth Equity firm currently manages $1 billion and provides $20-100 million of equity capital per company over the life of the investment. With offices in the US and UK, the firm is primarily looking for companies throughout North America and Europe.
The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, life sciences tools, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is open in terms of indications.
The firm looks for management teams that are very willing to work alongside them, and the firm generally looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Growth Equity Firm Invests Up to $100M in Life Science & Healthcare Companies Close to Commercialization
17 AugSurge in Family Offices: Investing in Healthcare
10 AugBy Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
In the ever-evolving finance and investment landscape, family offices have emerged as key players with the potential to drive significant change. These private wealth management firms, entrusted with managing the financial affairs of affluent families, have diversified their portfolios to include investments in a wide array of sectors. One sector that has garnered substantial attention in recent years is healthcare. The intersection of wealth preservation, a family’s medical health profile, and social impact have led many family offices to focus on investing in healthcare, a decision that promises financial returns, improves family legacy, and impacts global well-being.
LSN Collaboration with Stetson Family Office in 2019
LSN launched the Global Family Office BioForum in 2019 in collaboration with the Stetson Family Office to match Family Offices with angel groups, early-stage VCs, and KOLs to help identify and vet early-stage healthcare investment opportunities. This collaboration was an extension of Chuck Stetson’s visionary initiative on educating family offices to understand how they can impact chronic diseases like Alzheimer’s, Cancer, and Diabetes/Obesity and tackle big global healthcare issues through his Healthcare Impact Foundation. Over the years, the Global Family Office BioForum has witnessed many of these relationships fostered at LSN’s RESI partnering events grow into strategic alliances and investment syndicates that have helped Family Offices move into the early stage healthcare arena.
The Dynamics of Family Offices
Family offices, by their structure, cater to the unique financial needs of high-net-worth families. With a long-term perspective, they prioritize wealth preservation, growth, and the passing down of wealth to future generations. This approach aligns well with the characteristics of the healthcare sector, which, given its essential nature, presents a range of investment opportunities with the potential for both social impact and financial gains. New drug development can take a decade or more and cost hundreds of millions of dollars, while devices, diagnostics, and digital health technology can be developed in three to five years for five to 15 million. This breadth of choice allows a family office to execute its financial, healthcare, and social impact goals.
Why Healthcare?
As I have stated in the past, planet Earth is in the golden age of life science. Like other investor classes, family offices want a high return rate based on a timeline that matches their money management goals. The healthcare industry is undergoing rapid transformation, driven by technological advancements, changing demographics, and evolving consumer expectations. These shifts create fertile ground for investment, with opportunities that span pharmaceuticals, biotechnology, medical devices, telemedicine, healthcare IT, and more. The demand for innovative solutions to global health challenges is greater than ever, and family offices are positioning themselves as key contributors to this transformation.
Balancing Profit and Purpose
Family offices are uniquely positioned to balance profit with purpose. Investing in healthcare allows them to pursue financial returns and contribute to improving healthcare access, quality, and affordability. Many family offices see healthcare investments to align their financial goals with their desire to positively enhance their family legacy and society.
Driving Innovation
One of the remarkable aspects of family offices’ involvement in healthcare is their ability to drive innovation. By injecting capital into early-stage startups and research initiatives, family offices provide crucial support to ventures that may otherwise struggle to secure funding. This backing accelerates the development of groundbreaking therapies, technologies, and services, ultimately benefiting patients worldwide.
Announcing the Global Partnering Campaign, LSN’s Newest Product
10 AugBy Karen Deyo, Director of Product, Israel BD, LSN
Life Science Nation (LSN) is excited to announce that our newest product, the Global Partnering Campaign Salesforce App, is live! This is a new way to access the LSN Investor and Licensing Partner Database, taking the benefits of LSN’s curated data (10 categories of investors from 3,000 firms with 10,000 contacts), and combining it with LSN’s custom-developed fundraising campaign management tool.
What is the difference between the LSN Investor and Licensing Partner Database and the new GPC product?
The GPC product is a Salesforce App that has to be downloaded off of the Salesforce AppExchange and installed into the company’s Salesforce account. The LSN Investor and Licensing Partner Database gives you access to the same content without a subscription to Salesforce.
Do I need to subscribe to Salesforce to use the new GPC product?
Yes, this new product is available through Salesforce only. Using a CRM like Salesforce is a crucial tool for managing a fundraising campaign and tracking all of your contact with investors and licensing partners – ensuring no missed opportunities or dropped balls.
What do I need to do to get the GPC App?
If you are not already a Salesforce client, subscribe to Salesforce (Professional license or above required), go the Salesforce AppExchange, and find and install the Life Science Nation – Global Partnering Campaign (GPC) app. Once you have installed the app, you will need to subscribe to the Essential or Premium plan through this link and contact LSN at gpc@lifesciencenation.com for your onboarding with your BD representative. After the onboarding is complete, LSN staff will activate the GPC app, and you can start identifying your Global Target List of investors and licensing partners and begin your outreach!
Click here to watch a demo of the new product!
Interview with Shikha Sharma, Senior Director, Innovation at California Life Sciences (CLS)
10 Aug Shikha Sharma |
Interview with Shikha Sharma, Senior Director, Innovation at California Life Sciences
By Caitlin Dolegowski, Marketing Manager, LSN |
 Caitlin Dolegowski |
Caitlin Dolegowski (CD): Please introduce us to California Life Sciences.
Shikha Sharma (SS): California Life Sciences (CLS) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, CLS has served the community by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. On behalf of our more than 1,200 member organizations, CLS works to shape public policy, improve access to breakthrough technologies, educate lawmakers, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. In doing so, CLS fulfills its mission to protect and nurture California’s life sciences industry, empowering discoveries that lead to healthier lives around the world.
CD: What type of companies do California Life Sciences consider for membership?
SS: CLS members represent companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector.
CD: What stage of fundraising is California Life Sciences looking to support?
SS: The CLS Innovation & Entrepreneurship programs primarily support early-stage companies in fundraising stages from pre-seed to Series A. However, the broader CLS community encompasses members, companies, stakeholders, and pharma industry professionals with accessibility to later stage fundraising know-how and connections. Becoming part of CLS gives you access to a broad network that can directly and indirectly support companies in any stage of fundraising.
CD: Clearly, California Life Sciences, is in California. Though, not all your members are located in California. What are your geographic qualifications?
SS: We don’t have geographic qualifications, per se. CLS welcomes any organization that is looking to access, expand and/or maintain a foothold in what I would consider the most robust life sciences ecosystem worldwide.
CD: What works well for California Life Sciences in being a part of the RESI experience?
SS: As part of our portfolio of entrepreneurship services, CLS seeks to establish partnerships with respected partnering and investor conferences to aid our members in the fundraising journeys. Importantly, opportunities like RESI connects them with Seed and Series B investors, channel and licensing partners.
CD: What other information is important for companies to consider about California Life Sciences?
SS: California Life Sciences’ innovation and entrepreneurship initiatives connect life science startups to the resources needed to help them effectively scale their ventures. Our programs create a platform for accessing business partners, investors, foundations and patient advocacy organizations, peers, and other industry leaders.
Designed to nurture and advocate for emerging and diverse innovators from throughout the state, CLS offers advisory services, positioning for capital tools, access to capital through strategic partnerships and events and US market access resources to help in the development and commercialization of their business.
Hot Investor Mandate: USA-Based Multi Family Office Invests in Seed to Series A Life Science Companies, With Strong Interests in Oncology
10 AugA USA-based multi-family office invests across several sectors, with a focus on life science and healthcare. The firm typically seek opportunities in Seed to Series A rounds, with an initial check size ranging from $500K to $3M USD. Within life science and healthcare, approximately half the firm’s investments have been in companies related to oncology, which is an area of special interest to the firm. While most of their investments have been in the US, the firm will consider opportunities in other countries like Canada and Europe. The firm is typically a co-investor.
Within life science and healthcare, the firm is interested in biotech therapeutics, medtech, and is open to diagnostics and life science tools as well. The firm is agnostic to subsectors, although cell and gene therapy is one area of interest. The firm is open to considering companies at an early stage of development, from pre-clinical to phase I for therapeutics and from in-development to clinical stage for medical devices. The firm is open to devices across all classes. For indications, oncology stands out as a particular area of interest for the firm.
While the firm does not have special requirements regarding the founding or management team. The firm does place emphasis on partnering with experienced founders and value the expertise and track record of the founder.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Firm With US & Europe Offices Invests With a New Fund in Early-Stage Life Sciences With Opportunistic Mandate
10 AugA venture capital firm newly founded in 2023 and dually headquartered in the U.S. and Europe is looking to invest from its new fund in life science startups typically in the Series A round. Typical check size is flexible but ranges from $250k-2M. The firm is looking to invest in companies from the U.S., Europe, Israel, and the Middle East. The firm’s co-founder is NIH trained and has done consulting with the FDA, bringing their expertise to investments and companies.
The firm is investing in life science sectors including: 50% in therapeutics, 20% in medical devices, 20% in diagnostics, and 10% in health-tech. The firm is open to all modalities and technologies. In terms of therapeutics, the firm prefers companies that are Pre-Clinical up to Phase II and will not look farther than that. The firm is indication-agnostic and is open to looking at orphan diseases.
The firm may take a board seat on a case-by-case basis but does not have specific management team requirements. The firm can participate as a lead investor or co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: China-Based Global Pharmaceutical Seeks Innovative Drug Candidates for Strategic Partnership in Oncology, CNS, Autoimmune Disease, and More
10 AugOne of the leading fully integrated biopharmaceutical companies in China with multiple integrated R&D centers in US and China is actively seeking licensing/collaboration on development candidates with first-in-class or best-in-class potentials and commercial products with substantial market opportunities in China and worldwide.
The firm is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease.
The firm is looking for companies with capacity and experience to implement R&D plans. The firm is interested in incubating companies from scratch.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 